Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Veritas Genetics
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
Bergen Brunswig's hospital supply business has launched a preferred supplier program to help alternate site and some hospital customers lower costs through "focused, strategic" relationships. Such programs are gaining ground in the hospital supply business, but they raise issues--about the relationship of distributors to GPOs and distributors to manufacturers--that distributors may find vexing.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Curoverse, Inc.